Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat
2006

Modeling the Pharmacokinetics of ACE Inhibitors

Sample size: 11 publication Evidence: moderate

Author Information

Author(s): David G Levitt, Rik C Schoemaker

Primary Institution: University of Minnesota

Hypothesis

Can a human physiologically based pharmacokinetic (PBPK) model accurately describe the pharmacokinetics of ACE inhibitors like ramipril and ramiprilat?

Conclusion

The PBPK model can accurately describe the pharmacokinetics of ramipril and ramiprilat, providing insights into their absorption and metabolism.

Supporting Evidence

  • The model accurately describes individual variations in plasma concentrations of ramipril and ramiprilat.
  • The model incorporates realistic human physiological parameters.
  • The study highlights the importance of understanding tissue ACE inhibition for effective drug therapy.

Takeaway

This study created a computer model to understand how a heart medicine works in the body, helping doctors know how much to give patients.

Methodology

The model was applied to experimental data to describe the pharmacokinetics of ramipril and ramiprilat, incorporating factors like absorption, metabolism, and binding kinetics.

Limitations

The model's accuracy depends on the binding constants assumed, which may not reflect physiological conditions.

Participant Demographics

Healthy young males aged 19 to 28 years, non-obese.

Digital Object Identifier (DOI)

10.1186/1472-6904-6-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication